PL369337A1 - Związki spirohydantoinowe przydatne jako środki przeciwzapalne - Google Patents

Związki spirohydantoinowe przydatne jako środki przeciwzapalne

Info

Publication number: PL369337A1
Authority: PL; Poland
Prior art keywords: spiro; inflammatory agents; compounds useful; hydantoin compounds; hydantoin
Prior art date: 2001-10-01

Application number

PL02369337A

Other languages

English (en)

Inventor

T.G.Murali Dhar

Dominique Potin

Magaili Jeannine Blandine Maillet

Michele Launay

Eric Antoine Nicolai

Edwin J. Iwanowicz

Original Assignee

Bristol-Myers Squibb Company

Cerep Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-01

Filing date

2002-09-30

Publication date

2005-04-18

2002-09-30 Application filed by Bristol-Myers Squibb Company, Cerep Sa filed Critical Bristol-Myers Squibb Company

2005-04-18 Publication of PL369337A1 publication Critical patent/PL369337A1/pl

Links

QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 title 1
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)

PL02369337A 2001-10-01 2002-09-30 Związki spirohydantoinowe przydatne jako środki przeciwzapalne PL369337A1 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US32636101P	2001-10-01	2001-10-01
US35411302P	2002-02-04	2002-02-04
US40025902P	2002-08-01	2002-08-01

Publications (1)

Publication Number	Publication Date
PL369337A1 true PL369337A1 (pl)	2005-04-18

Family

ID=27406458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02369337A PL369337A1 (pl)	2001-10-01	2002-09-30	Związki spirohydantoinowe przydatne jako środki przeciwzapalne

Country Status (23)

Country	Link
US (4)	US6977267B2 (pl)
EP (1)	EP1432700B1 (pl)
JP (1)	JP4394442B2 (pl)
KR (1)	KR20040041649A (pl)
CN (1)	CN1596253A (pl)
AR (1)	AR036663A1 (pl)
AT (1)	ATE447565T1 (pl)
BR (1)	BR0213025A (pl)
CA (1)	CA2462112A1 (pl)
DE (1)	DE60234264D1 (pl)
ES (1)	ES2339107T3 (pl)
GE (1)	GEP20063767B (pl)
HR (1)	HRP20040311A2 (pl)
HU (1)	HUP0402338A3 (pl)
IL (1)	IL160990A0 (pl)
IS (1)	IS7197A (pl)
MX (1)	MXPA04002993A (pl)
NO (1)	NO20041339L (pl)
NZ (1)	NZ531870A (pl)
PE (1)	PE20030845A1 (pl)
PL (1)	PL369337A1 (pl)
RS (1)	RS26604A (pl)
WO (1)	WO2003029245A1 (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7550590B2 (en) *	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
ATE467616T1 (de) *	2003-04-11	2010-05-15	High Point Pharmaceuticals Llc	Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
US7700583B2 (en)	2003-04-11	2010-04-20	High Point Pharmaceuticals, Llc	11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20060041309A (ko) *	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7790734B2 (en) *	2003-09-08	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) *	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7199125B2 (en)	2003-10-02	2007-04-03	Bristol-Myers Squibb Company	Spiro-cyclic compounds useful as anti-inflammatory agents
AU2004287875B2 (en)	2003-11-05	2011-06-02	Bausch + Lomb Ireland Limited	Modulators of cellular adhesion
AU2004305075A1 (en)	2003-12-19	2005-07-07	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies
NZ550102A (en)	2004-02-24	2010-10-29	Univ California	Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102127057A (zh)	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
JP2008501714A (ja) *	2004-06-04	2008-01-24	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
MX2007000214A (es)	2004-07-01	2007-05-10	Asubio Pharma Co Ltd	Derivado de tienopirazol que tiene actividad inhibidora de pde 7.
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7375237B2 (en)	2004-08-18	2008-05-20	Bristol-Myers Squibb Company	Pyrrolizine compounds useful as anti-inflammatory agents
TW200616634A (en)	2004-10-01	2006-06-01	Bristol Myers Squibb Co	Crystalline forms and process for preparing spiro-hydantoin compounds
CA2585797C (en) *	2004-11-10	2015-01-06	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
US8110581B2 (en)	2004-11-10	2012-02-07	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
US20060142319A1 (en) *	2004-12-14	2006-06-29	Bang-Chi Chen	Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7186727B2 (en)	2004-12-14	2007-03-06	Bristol-Myers Squibb Company	Pyridyl-substituted spiro-hydantoin compounds and use thereof
WO2006068978A2 (en) *	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Dipeptidyl peptidase inhibitors
WO2006102476A2 (en) *	2005-03-21	2006-09-28	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
US20090117197A1 (en) *	2005-03-21	2009-05-07	Vicus Therapeutics Llc	Compositions and methods for ameliorating cachexia
US20080033027A1 (en) *	2005-03-21	2008-02-07	Vicus Therapeutics Spe 1, Llc	Drug combination pharmaceutical compositions and methods for using them
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
US20090258862A1 (en) *	2005-08-29	2009-10-15	Colletti Steven L	Niacin receptor agonists, compositions containing such compounds and methods of treatment
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
PL1931350T5 (pl) *	2005-09-14	2021-11-15	Takeda Pharmaceutical Company Limited	Podanie inhibitorów dipeptydylo-peptydazy
EP2073810B1 (en) *	2006-09-13	2011-08-31	Takeda Pharmaceutical Company Limited	Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CN101360723A (zh) *	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
KR20080066949A (ko) *	2005-10-11	2008-07-17	인터뮨, 인크.	바이러스 복제 억제제
US8926990B2 (en) *	2009-10-13	2015-01-06	Rutgers, The State University Of New Jersey	Treatment and diagnosis of inflammatory disorders and HIV
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
LT2656842T (lt)	2006-03-27	2016-09-26	The Regents Of The University Of California	Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1999108A1 (en) *	2006-03-28	2008-12-10	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
KR101456722B1 (ko)	2006-03-29	2014-10-31	더 리전트 오브 더 유니버시티 오브 캘리포니아	디아릴티오히단토인 화합물
US7740064B2 (en)	2006-05-24	2010-06-22	Baker Hughes Incorporated	System, method, and apparatus for downhole submersible pump having fiber optic communications
JP2010501567A (ja)	2006-08-24	2010-01-21	ノバルティスアクチエンゲゼルシャフト	代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR20090053923A (ko)	2006-09-22	2009-05-28	노파르티스 아게	헤테로시클릭 유기 화합물
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101595105B (zh)	2006-12-20	2013-01-23	诺瓦提斯公司	作为scd抑制剂的2-取代的5元杂环化合物
EP2128163A1 (en)	2007-01-25	2009-12-02	Takeda Pharmaceutical Company Limited	Spiro-ring compound
WO2008096746A1 (ja) *	2007-02-06	2008-08-14	Takeda Pharmaceutical Company Limited	スピロ化合物およびその用途
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US8258313B2 (en) *	2007-07-19	2012-09-04	Tokuyama Corporation	Compound having hydantoin ring and method of producing the same
ES2630406T3 (es)	2007-10-19	2017-08-21	Sarcode Bioscience Inc.	Composición y procedimientos para el tratamiento de la retinopatía diabética
TWI469971B (zh)	2007-10-26	2015-01-21	Univ California	二芳基乙內醯脲類化合物
WO2009061830A1 (en) *	2007-11-06	2009-05-14	Massachusetts Eye & Ear Infirmary	Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
WO2010141330A1 (en)	2009-06-02	2010-12-09	Boehringer Ingelheim International Gmbh	DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
RU2012114770A (ru)	2009-09-04	2013-10-10	Вандербилт Юниверсити	АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
WO2011103202A2 (en)	2010-02-16	2011-08-25	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
AU2013305759C1 (en)	2012-08-23	2018-01-18	Janssen Biopharma, Inc.	Compounds for the treatment of paramoxyvirus viral infections
SG11201501870RA (en)	2012-09-26	2015-04-29	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201907684PA (en)	2013-01-15	2019-10-30	Aragon Pharmaceuticals Inc	Androgen receptor modulator and uses thereof
NZ716822A (en) *	2013-08-21	2017-10-27	Alios Biopharma Inc	Antiviral compounds
MX2016013049A (es) *	2014-04-04	2017-04-27	X-Rx Inc	Inhibidores de autotaxina espirociclicos sustituidos.
WO2016028971A1 (en)	2014-08-21	2016-02-25	Bristol-Myers Squibb Company	Tied-back benzamide derivatives as potent rock inhibitors
MA41614A (fr)	2015-02-25	2018-01-02	Alios Biopharma Inc	Composés antiviraux
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017170830A1 (ja) *	2016-03-31	2017-10-05	武田薬品工業株式会社	複素環化合物
AU2018351714A1 (en)	2017-10-16	2020-04-30	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
JP2024502909A (ja) *	2020-12-24	2024-01-23	アルマルソン、オーン	キサントフィル誘導体
CN115536494B (zh) *	2022-10-31	2023-12-01	苏州诚和医药化学有限公司	1-(4-溴苯基)-1,4-丁二醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1331757C (en) *	1988-02-29	1994-08-30	Janssen Pharmaceutica Naamloze Vennootschap	5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5346913A (en) *	1992-05-26	1994-09-13	Rohm And Haas Company	N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) *	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) *	1994-01-05	2003-02-21	Hoechst Marion Roussel Inc	New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2741342B1 (fr) *	1995-11-22	1998-02-06	Roussel Uclaf	Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
US6890915B2 (en)	2001-05-25	2005-05-10	Bristol-Myers Squibb Pharma Company	Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)

2002
- 2002-09-30 CA CA002462112A patent/CA2462112A1/en not_active Abandoned
- 2002-09-30 KR KR10-2004-7004778A patent/KR20040041649A/ko not_active Withdrawn
- 2002-09-30 HR HR20040311A patent/HRP20040311A2/hr not_active Application Discontinuation
- 2002-09-30 ES ES02800414T patent/ES2339107T3/es not_active Expired - Lifetime
- 2002-09-30 AT AT02800414T patent/ATE447565T1/de not_active IP Right Cessation
- 2002-09-30 WO PCT/US2002/031283 patent/WO2003029245A1/en not_active Ceased
- 2002-09-30 HU HU0402338A patent/HUP0402338A3/hu unknown
- 2002-09-30 RS YU26604A patent/RS26604A/sr unknown
- 2002-09-30 CN CNA028238540A patent/CN1596253A/zh active Pending
- 2002-09-30 PL PL02369337A patent/PL369337A1/pl not_active Application Discontinuation
- 2002-09-30 EP EP02800414A patent/EP1432700B1/en not_active Expired - Lifetime
- 2002-09-30 GE GE5595A patent/GEP20063767B/en unknown
- 2002-09-30 IL IL16099002A patent/IL160990A0/xx unknown
- 2002-09-30 MX MXPA04002993A patent/MXPA04002993A/es unknown
- 2002-09-30 BR BR0213025-4A patent/BR0213025A/pt not_active IP Right Cessation
- 2002-09-30 AR ARP020103695A patent/AR036663A1/es unknown
- 2002-09-30 NZ NZ531870A patent/NZ531870A/en unknown
- 2002-09-30 JP JP2003532494A patent/JP4394442B2/ja not_active Expired - Fee Related
- 2002-09-30 DE DE60234264T patent/DE60234264D1/de not_active Expired - Lifetime
- 2002-10-01 PE PE2002000971A patent/PE20030845A1/es not_active Application Discontinuation
- 2002-10-01 US US10/262,182 patent/US6977267B2/en not_active Expired - Lifetime
2004
- 2004-03-24 IS IS7197A patent/IS7197A/is unknown
- 2004-03-31 NO NO20041339A patent/NO20041339L/no not_active Application Discontinuation
- 2004-05-24 US US10/852,576 patent/US7078420B2/en not_active Expired - Lifetime
- 2004-06-16 US US10/869,292 patent/US20050004153A1/en not_active Abandoned
- 2004-06-16 US US10/869,289 patent/US20040259897A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20041339D0 (no)	2004-03-31
CA2462112A1 (en)	2003-04-10
US20050004153A1 (en)	2005-01-06
GEP20063767B (en)	2006-03-10
EP1432700A1 (en)	2004-06-30
HUP0402338A2 (hu)	2005-02-28
DE60234264D1 (de)	2009-12-17
WO2003029245A1 (en)	2003-04-10
KR20040041649A (ko)	2004-05-17
US20040259897A1 (en)	2004-12-23
US20040009998A1 (en)	2004-01-15
US6977267B2 (en)	2005-12-20
EP1432700A4 (en)	2004-12-22
US7078420B2 (en)	2006-07-18
AR036663A1 (es)	2004-09-22
CN1596253A (zh)	2005-03-16
BR0213025A (pt)	2004-10-05
RS26604A (sr)	2006-12-15
IL160990A0 (en)	2004-08-31
ES2339107T3 (es)	2010-05-17
MXPA04002993A (es)	2004-07-15
HRP20040311A2 (en)	2005-02-28
NZ531870A (en)	2005-08-26
JP2005510476A (ja)	2005-04-21
IS7197A (is)	2004-03-24
US20040248920A1 (en)	2004-12-09
JP4394442B2 (ja)	2010-01-06
NO20041339L (no)	2004-05-24
PE20030845A1 (es)	2003-10-23
HK1063467A1 (en)	2004-12-31
ATE447565T1 (de)	2009-11-15
HUP0402338A3 (en)	2008-10-28
EP1432700B1 (en)	2009-11-04

Legal Events

Date	Code	Title	Description
2011-03-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL160990A0 (en)	2004-08-31	Spiro-hydantoin compounds useful as anti-inflammatory agents
IL144897A0 (en)	2002-06-30	Compounds useful as anti-inflammatory agents
AU2002349297A8 (en)	2003-06-17	Statin-like compounds
GB0101996D0 (en)	2001-03-14	Organtic compounds
GB0102668D0 (en)	2001-03-21	Compounds
GB0130335D0 (en)	2002-02-06	Compounds
MXPA03009361A (es)	2004-01-29	Compuestos de urea utilies como agentes anti-inflamatorios.
GB0102665D0 (en)	2001-03-21	Compounds
GB0108102D0 (en)	2001-05-23	Compounds
GB0102673D0 (en)	2001-03-21	Compounds
AU2003282510A8 (en)	2004-05-04	Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
PL369829A1 (pl)	2005-05-02	Podstawione związki 1H-chinolin-2-onowe
EP1395259A4 (en)	2005-01-26	USE OF URAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS
AU2001253517A1 (en)	2002-10-28	Compounds useful as anti-inflammatory agents
GB0105098D0 (en)	2001-04-18	Compounds
GB0111645D0 (en)	2001-07-04	Therapeutically useful compounds
GB0125123D0 (en)	2001-12-12	Therapeutically useful compounds
GB0107643D0 (en)	2001-05-16	Therapeutically useful compounds
GB0127159D0 (en)	2002-01-02	Therapeutically useful compounds
GB0111642D0 (en)	2001-07-04	Therapeutically useful compounds
GB0107644D0 (en)	2001-05-16	Therapeutically useful compounds
GB0117145D0 (en)	2001-09-05	Therapeutically useful compounds
GB0109999D0 (en)	2001-06-13	Therapeutically useful compounds
GB0102661D0 (en)	2001-03-21	Compounds
GB0100183D0 (en)	2001-02-14	Vovel compounds